Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xenical Should Be Pulled From Market Due To Possible Precancer Ties, Public Citizen Says

This article was originally published in The Pink Sheet Daily

Executive Summary

A petition from the advocacy group comes days after GSK receives an “approvable” letter for the obesity drug’s Rx-to-OTC switch.

You may also be interested in...



Acomplia To Launch In July In Europe For Obesity Indication

Sanofi-Aventis’ rimonabant is currently “approvable” at FDA for obesity.

Acomplia To Launch In July In Europe For Obesity Indication

Sanofi-Aventis’ rimonabant is currently “approvable” at FDA for obesity.

Glaxo's Alli Favored For OTC Weight-Loss Use By FDA Joint Panel

FDA's Nonprescription Drugs and Endocrinologic & Metabolic Drugs advisory committees voted 11-3 in favor of making Xenical available over the counter.

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel